Antimycotic activity of Bacillus subtilis 534 strain: the bases of the probiotic sporobacterin


DOI: https://dx.doi.org/10.18565/epidem.2018.3.51-6

Gabrielyan N.I., Drabkina I.V., Krupenio T.V., Demyankova M.V., Malanicheva I.A., Vasilyeva B.F., Efimenko T.A., Sumarukova I.G., Glukhova A.A., Boykova Yu.V., Malkina N.D., Udalova V.V., Alferova V.A., Korshun V.A., Efremenkova O.V.

1 Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia, Moscow, Russia; 2 G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia
Objective. To investigate the antimycotic activity of the probiotic strain Bacillus subtilis 534 in the in vitro cultivation conditions.
Materials and methods. The taxonomic identification of the isolated pathogenic fungi and their antimycotic sensitivity/resistance determined on an automated MicroScan WalkAway-96 plus System. The strain B. subtilis 534 was grown under submerged cultivation conditions. The antimycotic activity of the culture liquid was determined by the agar diffusion assay. Thirty-six clinical isolates of the pathogenic fungi Candida albicans, C. catenulata, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, С. tropicalis, Cryptococcus neoformans, and Trichosporon spp. and the algae Prototheca spp. were used as tests for the determination of their antimycotic activity.
Results. The clinical isolates differ in resistance/sensitivity to the antimycotics amphotericin, miconazole, ketoconazole, itraconazole, and fluconazole, whereas 10 isolates are resistant to all five of these drugs. Thirty-four out of the 36 clinical isolates are sensitive to the culture liquid of the strain B. subtilis 534 and to its isolated active components. Presumably, strain 534 in the human intestine also forms antimicrobial compounds that are active against pathogenic fungi, which is responsible for its antimycotic efficacy.
Conclusion. The long-term medical application of the probiotic sporobacterin that is B. subtilis 534 spore suspension suggests that the latter is effective and free of side effects.
Keywords: antimycotic activity, probiotic sporobacterin, Bacillus subtilis 534, resistance
Read entire article

Literature

  1. World Health Organization. Antimicrobial resistance. 2016. URL: http://www.who.int/mediacentre/factsheets/fs194/en/
  2. Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline in 2013. J.Antibiot. 2013; 66(10): 571–91.
  3. Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline at the end of 2015. J. Antibiot. 2017; 70(1): 3–24.
  4. Pohilenko V.D., Perelygin V.V. [Probiotics based on spore-forming bacteria and their safety]. Himicheskaya i biologicheskaya bezopasnost’ 2007; 32–33(2–3): 20–41. (In Russ.).
  5. Skrypnik I.N., Maslova A.S. [Modern spore-forming probiotics in clinical practice]. Suchasna gastroenterologiya 2009; 3(47): 81–90. (In Russ.).
  6. Savust’yanenko A.V. [Mechanisms of action of probiotics based on Bacillus subtilis]. Aktual’naya infektologiya 2016; 2(11): 35–44. (In Russ.).
  7. Sanders M.E., Morelli L., Tompkins T.A. Sporeformers as Human Probiotics: Bacillus, Sporolactobacillus, and Brevibacillus. Comprehensive reviews in food science and food safety 2003; 2(3): 101–10. DOI: 10.1111/j.1541-4337.2003.tb00017.x
  8. Cutting S.M. Bacillus probiotics. Food Microbiol. 2011; 28: 214e220. DOI:10.1016/j.fm.2010.03.007.
  9. Sorokulova I. Modern Status and Perspectives of Bacillus Bacteria as Probiotics J. Prob. Health. 2013; 1(4): e106.
  10. Nikitenko V.I., Polyakova B.C., Nikitenko M.V. [The drug is sporobacterin. New data on the mechanism of action of this and other living bacterial preparations]. Nauchnyj vestnik Tyumenskoj medicinskoj akademii 2001; (2): 70–2. (In Russ.).
  11. Gabriehlyan N.I., Davydov D.S., Gorskaya E.M. [Use of sporobacterin in the postoperative period in patients of the cardiosurgical profile. Antagonism in vitro of sporobacterin against nosocomial strains of bacteria]. Vestnik transplantologii i iskusstvennykh organov 2008; (6): 12–8. (In Russ.).
  12. Gabriehlyan N.I., Gorskaya E.M., Krupenio T.V., Zenkova V.A., Efimenko T.A., Malanicheva I.A., Sumarukova I.G., Efremenkova O.V., Evlashkina V.F., Davydov D.S. [Evaluation of the antimicrobial activity of the bacillary probiotic Bacillus subtilis (strain 534). Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2016; (1): 41–7. (In Russ.).
  13. Efremenkova O.V., Gabriehlyan N.I., Malanicheva I.A., Efimenko T.A., Terekhova L.P., Udalova V.V., Gluhova A.A., Rogozhin E.A., Alferova V.A., Korshun V.A., Kubanova M.H., Drabkina I.V., Krupenio T.V. [Antibiotic activity of the probiotic strain Bacillus subtilis 534 for clinical isolates of Acinetobacter baumannii. Antibiotiki i himioterapiya 2016; 61(9–10): 3–7. (In Russ.).
  14. Osipova I.G., Sorokulova I.B., Vasil’eva E.A., Budanova E.V. [Preclinical trials of new spore probiotics]. Vestnik Rossiyskoy Akademii meditsinskikh nauk 2005; (12): 36–40. (In Russ.).
  15. Leser T.D., Knarreborg A., Worm J. Germination and outgrowth of Bacillus subtilis and Bacillus licheniformis spores in the gastrointestinal tract of pigs. J. Appl. Microbiol. 2008; 104(4): 1025–33.

For citations: Габриэлян Н.И., Драбкина И.В., Крупенио Т.В., Демьянкова М.В., Маланичева И.А., Васильева Б.Ф., Ефименко Т.А., Сумарукова И.Г., Глухова А.А., Бойкова Ю.В., Малкина Н.Д., Удалова В.В., Алферова В.А., Коршун В.А., Ефременкова О.В. Антимикотическая активность штамма Bacillus subtilis 534 – основы пробиотика споробактерина. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2018; (3):51–6


About the Autors

For correspondence:
Olga V. Efremenkova, Cand. Biol. Sci., Head, Sector for Searching for Natural Compounds that Overcome Bacterial Resistance, Department of Microbiology, G.F. Gauze Research Institute for Search for New Antibiotics
Address: 11, Bolshaya Pirogovskaya St., Build. 1, Moscow119021, Russia
Telephone: +7(499) 255-77-31
E-mail: ovefr@yandex.ru
ORCID: http://orcid.org/0000-0003-3131-1031
Information about the authors:
Nina I. Gabrielyan, MD, Head, Department of Endotoxicosis and Pyoseptic Complications, Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia, Moscow, Russia; е-mail: labgso@mail.ru; ORCID: http://orcid.org/0000-0003-1941-8311
Irina V. Drabkina, Bacteriologist, Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia, Moscow, Russia; е-mail: drabkina58@mail.ru; ORCID: http://orcid.org/0000-0002-9528-3490
Tatiana V. Кrupenio, Laboratory Researcher, Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia, Moscow, Russia; e-mail: ypsa89@mail.ru laboratorian; ORCID http://orcid.org/0000-0002-7903-534X
Maria V. Demyankova, Laboratory Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: mary_bunny@mail.ru; ORCID: http://orcid.org/0000-0003-0085-1668
Irina A. Malanicheva, Cand. Biol. Sci., Senior Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: malanicheva.irina@yandex.ru; ORCID: http://orcid.org/0000-0002-7623-6146
Byazilya F. Vasilyeva, Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; е-mail: bfvas@yandex.ru; ORCID: http://orcid.org/0000-0001-9077-1965
Tatiana A. Еfimenko, Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: efimen@inbox.ru; ORCID: http://orcid.org/0000-0001-9632-6854
Irina G. Sumarukova, Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: noks59@yandex.ru; ORCID: http://orcid.org/0000-0001-7750-7983
Alla A. Glukhova, Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: alglukhova@yandex.ru; ORCID: http://orcid.org/0000-0003-0561-4709
Yulia V. Boykova, Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: boykowa.yulya@yandex.ru; ORCID: http://orcid.org/0000-0002-1128-7460
Natalia D. Malkina, Cand. Biol. Sci., Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: utvar@blagoslovenie.su; ORCID: http://orcid.org/0000-0002-8566-0010
Viktoria V. Udalova, Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: viudalova@yandex.ru; ORCID: http://orcid.org/0000-0002-0392-8379
Vera A. Alferova, Researcher, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: alferovava@gmail.com; ORCID: http://orcid.org/0000-0002-8961-5890
Vladimir A. Korshun, ChemD, Head, Laboratory Chemical Study of Biologically Active Compounds of Microbial Origin, G.F. Gauze Research Institute for Search for New Antibiotics, Moscow, Russia; e-mail: v-korshun@yandex.ru; ORCID: http://orcid.org/0000-0001-9436-6561


Similar Articles

Back to Content

Бионика Медиа